Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab in CRSwNP (ANCHOR-2)
NCT05281523Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2022
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing Depemokimab + SOC with Placebo + SOC (2 arms). Primary endpoints: Change From Baseline in Total Endoscopic Nasal Polyps (NP) Score at 52 weeks and Change From Baseline in Mean Nasal Obstruction Score Using Verbal Response Scale at 52 weeks. Started Apr 2022; status: completed.
02
Drugs
depemokimab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT05281523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05281523.